Alyssa’s Story
When I was 12, I started feeling really tired. I’d fall asleep during break and lunchtime at school,…
Supporting Patients In London
Find out more about how Cure Leukaemia's funding impacts patients in London and surrounding areas
Cure Leukaemia is proud to play a vital role in supporting blood cancer patients across London. At both King’s College Hospital London, University College London Hospital (UCLH) and The Royal Marsden, we fund a dedicated clinical research nurse who ensures patients have access to pioneering treatments and potentially life-saving clinical trials.
Our support also extends to young patients and their families, with Great Ormond Street Hospital (GOSH), St Mary’s Hospital London and UCLH, being part of the ATICUS Network – a groundbreaking initiative bringing together leading centres to deliver world-class care and research opportunities.
Together, these efforts help to provide hope, innovation, and improved outcomes for people facing blood cancer in our city.
Clinical Trials Taking Place In London
Discover which clinical trials have been delivered in London, with support of funding from Cure Leukaemia
VICTOR
The VICTOR trial is a groundbreaking clinical trial available at TAP Centres across the UK, comparing a combination of two targeted drugs to traditional chemotherapy. This trial, specifically designed for AML patients aged 60 and over, offered a less toxic and more manageable treatment option.
STELLAR
A Phase 2 randomised trial for adults with Richter’s syndrome, a rare and aggressive form of lymphoma. The STELLAR trial is the first randomised trial for Richter’s syndrome in the UK, and it demonstrates the nation’s growing ability to run trials in rare diseases. The study also includes crucial translational research that will help tailor future therapies.
AMMO
One of the TAP Network’s highest recruiting studies, AMMO trial tests a new drug in treating and extending the lives of patients with a rare bone marrow cancer, where treatment options are very limited. The treatment can be taken orally at home, making it much more convenient for patients. The trial has just concluded and results are expected to be published at the end of 2025.
PRIZM+
This pioneering Phase 2 platform trial is evaluating Zanubrutinib therapy in adults with relapsed brain lymphoma. In the first year, 20 patients with this rare and aggressive blood cancer were recruited, with first results due to be presented at an international conference next month. Later this year, recruitment will re-commence for a further 20 patients using a world-first three-drug combination, offering long-term hope for those facing limited treatment options.
Inspiring Patient Stories in London
Austin’s Story
Austin, now 16, has spent nearly eight years fighting Acute Lymphoblastic Leukaemia (ALL). For many children, treatment for…
Mike’s Story
In 2018, Mike was diagnosed with Hairy Cell Leukaemia (HCL) – a rare, slow-growing type of blood cancer that affects…
Harry’s Story
Debbie and Matt’s son Harry was diagnosed in 2013 with Acute Lymphoblastic Leukaemia (ALL) at only two years…
Want to support patients in London?
Get involved and support Cure Leukaemia as we continue the fight against blood cancer, helping us fund more Research Nurses and delivering more clinical trials.
Upcoming Events In London
Get involved in some of our upcoming events in London and raise vital funds to help us continue to support patients across the region
London 2 Brighton
London 2 Brighton, register interest for this one day sportive raising funds for blood cancer patients.
Make a Donation
By donating to Cure Leukaemia, you can help us continue our funding across London, bringing hope to patients and their families and helping us move closer to a cure